Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development.

Lampson, Benjamin L; Nishino, Mizuki; Dahlberg, Suzanne E; Paul, Danie; Santos, Abigail A; Jänne, Pasi A; Oxnard, Geoffrey R

Lampson, Benjamin L; Nishino, Mizuki; Dahlberg, Suzanne E; Paul, Danie; Santos, Abigail A; Jänne, Pasi A; Oxnard, Geoffrey R.

Afiliación

Lampson BL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Nishino M; Department of Radiology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
Dahlberg SE; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Paul D; Department of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.
Santos AA; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Oxnard GR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Cancer ; 122(22): 3456-3463, 2016 Nov 15.

Article en En | MEDLINE | ID: mdl-27525836

Palabras clave

epidermal growth factor receptor (EGFR) gene; erlotinib; molecular-targeted therapy; nonsmall cell lung carcinoma; pharmacokinetics

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancer Año: 2016 Tipo del documento: Article